Join Spotlight Family Office Group for an informative webinar featuring Lumicell.
Lumicell is a breakthrough surgical cancer company that is developing a drug & device that is designed to allow surgeons to detect and remove cancer that is missed in a first surgery, starting with breast cancer. Currently between 2 to 4 out of 10 patients having breast conserving surgery (lumpectomy) require a second surgery because they have a positive margin, implying cancer is left behind. Additionally, clinical studies have shown that up to 19% of patients have tumor completely missed by current standards of care. Lumicell addresses these gaps and is currently raising equity to support final approval and commercialization, driving revenue growth through 2024 which builds to $300M annually by year 5.
The Lumicell Direct Visualization System was designed and developed by MIT engineers in partnership with leading breast cancer surgeons to fit seamlessly within the existing surgical workflow. Lumicell is investigating the use of its therapy in patients undergoing surgery for breast cancer, Peritoneal Metastasis, GI cancers, and sarcoma.
Lumicell Highlights:
- Lumicell’s pan-cancerous solution to improve surgical outcomes – finding cancer missed – is positioned to lead in the emerging fluorescence guided surgical oncology space, reaching $300M in annual breast cancer revenue by year 5.
- Program largely de-risked with strong pivotal clinical trial data, New Drug Application (NDA) filed, and Premarket Approval (PMA) filing in Q2. On track for approval in Q4 followed by commercial launch in early Q1 2024.
- Lumicell is finalizing a commercial partnership with a market-leading medical device company to accelerate and augment Lumicell’s launch activities.
For more information please contact Matthew T. Sheridan at Matthew@SpotlightFamilyOffice.com.